Floatz logo

Arimidex

Endometrioid Endometrial Cancer

Memorial Sloan Kettering Cancer CenterPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Endometrioid Endometrial Cancer cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC
Tirzepatide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Copanlisib
NRG Oncology
Phase 2CCC

View all 14 →

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →